Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
Date:3/15/2011

cer (GPR182) and cognitive disorders (GPR12). Together with the three previously unlocked orphans linked to squamous cell carcinoma (GPR87), obesity (GPR85) and appetite control (GPR101), Omeros has now successfully unlocked five orphan GPCRs for drug development.
  • Announced the publication of an article regarding one of its antifibrinolytic agents in the February 11, 2011 issue of the Journal of Biological Chemistry, which was selected by the editors as one of the top one percent of papers reviewed by the Journal in terms of significance and overall importance.
  • Confirmed that OMS103HP is eligible to be submitted for marketing approval in the European Union through the European Medicines Agency centralized procedure. OMS103HP is Omeros' lead product candidate currently in a Phase 3 clinical program evaluating the drug's safety and ability to improve postoperative joint function and reduce pain following anterior cruciate ligament reconstruction surgery.  
  • Acquired GPCR assay technology, comprised of patents and other intellectual property rights, from Patobios Limited for a total of $10.8 million.

  • About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and two from its addiction franchise. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/5/2015)... SUNNYVALE, Calif. , May 5, 2015  Accuray ... scheduled to present at the Bank of America Merrill ... on Tuesday, May 12, 2015 at 2:20pm ... presentation will be available on the Investor Relations page ... webcast replay of the presentation will begin approximately one ...
    (Date:5/5/2015)... , May 5, 2015  Image Stream Medical, a ... agreement with MedAssets, one of the largest group purchasing ... United States.  Under terms of the three-year agreement, Image ... services will be made available to MedAssets members beginning ... partnership, Image Stream Medical CEO Eddie Mitchell ...
    (Date:5/5/2015)... , May 05, 2015 Research and ... the addition of the "Clinical Laboratory,Molecular Diagnostics ... 2015 to 2019 - Latin America, Africa and ... A market that just keeps on ... benefit from the explosion in biotechnology, especially genomics. ...
    Breaking Medicine Technology:Image Stream Medical Announces Agreement with MedAssets 2Latin America, Africa and Middle East Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2
    ... VEGAS, June 28, 2011 The pharmacy made the decision ... of its customers. The fact Xpressdelivery.com offered cheapest Viagra ... of the world, and their desire to see more drugs ... was only logical. After giving the matter most careful consideration ...
    ... June 28, 2011 In strong collaboration with clinical ... compact version of the LokomatPro that offers greater system ... device in 2001, the LokomatPro has established itself as ... patients with neurological diseases and injuries resulting in gait ...
    Cached Medicine Technology:Xpressdelivery.com Expanded Its Drug List Adding Most Demanded Generic Medications 2Hocoma Launches New Version of its Established Gait Training Device LokomatPro 2
    (Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Optimity) will present at the 24th ... at 1:15 p.m. MT in Scottsdale, AZ. WEDI, ... nation’s leading nonprofit authority on the use of ... exchange. Donald Graf, National Director of Telemedicine for ...
    (Date:5/5/2015)... (PRWEB) May 05, 2015 From ... the established leader in enabling enterprise collaboration ... to help customers speed up and simplify the ... technologies, AvePoint Solutions for Office 365 ... faster while ensuring sustainable user adoption and effectively ...
    (Date:5/5/2015)... Sunny skies and cool temperatures made for great ... runners and walkers participated in Global Lyme Alliance’s (GLA) inaugural ... , The 5K and 10K runs and 1-and 3-mile walks ... raise funds for tick-borne disease research. The “Lyme Walk and ... merger of Lyme Research Alliance (LRA) and Tick-Borne Disease ...
    (Date:5/5/2015)... " QuickPick Travel ” was featured on ... a look small, medium, and large businesses making an impact ... a business expert, conducted the business review and shared with ... to three weeks of vacation for free. , Vacations are ... explore the world. And when people are preparing for vacations, ...
    (Date:5/5/2015)... 2015 Information Innovators Inc. ... the federal government, today announced its acquisition of ... provides solutions exclusively to federal government customers through ... cyber security, health services, and program management support. ... credentials as a Third Party Assessment Organization (3PAO) ...
    Breaking Medicine News(10 mins):Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
    ... REVENUES UP 35% VERSUS FULL YEAR 2006, BRANCHBURG, ... today reported financial results for the fourth,quarter and full ... Executive Officer, will host a conference call today at ... year financial results., Fourth Quarter 2007 Results, ...
    ... Physicians Report Satisfaction with GlaxoSmithKline,s Advair and,Boehringer ... Novel, Anti-Inflammatory Drug, According to a New ... Feb. 27 Decision Resources, one of ... on pharmaceutical and,healthcare issues, finds that surveyed ...
    ... EXTON, Pa., Feb. 27 ViroPharma Incorporated,(Nasdaq: VPHM ) ... months ended December 31, 2007., Key events since ... Drug Designation received for Camvia(TM) (maribavir); -- Patient enrollment ... cell and solid organ transplant patients; ...
    ... Body, Mind & Spirit, VAIL, Colo., Feb. ... healthcare, Next Step(R) Institute of Integrative,Medicine, Inc., headquartered ... recently announced its 2008 series of life-changing,Wellness Weeks ... Institute Wellness Weeks are six-night, five-day programs,that promote ...
    ... Overweight Hispanic children with normal blood glucose (sugar) levels showed ... to developing both type 2 diabetes and cardiovascular disease, says ... Center. , The study, published in the March issue of ... already known to be at high risk for developing type ...
    ... new article suggests that the United States government ... Cuba into a biomedical research institute dedicated to ... the open-access journal PLoS Neglected Tropical Diseases, Editor-in-Chief ... be in an optimal position to directly address ...
    Cached Medicine News:Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status 2Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 10Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 11Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 2Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 3Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 4Health News:Overweight Hispanic children shown to have vascular inflammation 2Health News:From detainee facility to health advocacy center: A new role for Guantanamo? 2
    Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
    Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
    Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C....
    For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl....
    Medicine Products: